INT196919

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2006
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 8
Disease Relevance 6.14
Pain Relevance 2.55

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Braf) plasma membrane (Braf) nucleus (Braf)
kinase activity (Braf) cytoplasm (Braf)
Anatomy Link Frequency
pituitary 1
Braf (Mus musculus)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 444 98.80 Very High Very High Very High
imagery 12 92.80 High High
Inflammation 42 88.04 High High
cytokine 30 86.84 High High
headache 1 79.08 Quite High
Kinase C 6 73.36 Quite High
spinal inflammation 60 60.48 Quite High
Arthritis 60 59.20 Quite High
psoriasis 12 31.44 Quite Low
Glutamate 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pituitary Cancer 27 99.28 Very High Very High Very High
Rheumatoid Arthritis 444 98.80 Very High Very High Very High
Melanoma 5 98.32 Very High Very High Very High
Cancer 55 95.04 Very High Very High Very High
Adenoma 4 92.96 High High
Death 6 91.96 High High
Arthritis 72 88.04 High High
Disease Progression 1 85.36 High High
INFLAMMATION 30 81.60 Quite High
Hypopituitarism 1 79.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
BRAF activation is regulated by both its N and C terminal domains.
Regulation (regulated) of BRAF
1) Confidence 0.32 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991030 Disease Relevance 0.70 Pain Relevance 0.37
We then analysed the effects of anti-BRAF autoantibodies isolated from RA patients on the kinase activity of BRAF.
Spec (analysed) Regulation (effects) of anti-BRAF associated with rheumatoid arthritis
2) Confidence 0.28 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991030 Disease Relevance 1.00 Pain Relevance 0.53
To identify peptide targets of anti-BRAF autoantibodies, we used 40 overlapping 20 mers encompassing the entire catalytic domain of BRAF to analyze RA sera.
Regulation (targets) of anti-BRAF associated with rheumatoid arthritis
3) Confidence 0.28 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991030 Disease Relevance 0.74 Pain Relevance 0.42
BRAF is also an interesting target for autoantibodies.
Regulation (target) of BRAF
4) Confidence 0.19 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991030 Disease Relevance 0.70 Pain Relevance 0.35
The binding of autoantibodies to BRAF's catalytic domain may result in a change in BRAF conformation and stabilise BRAF in an active conformation allowing the kinase domain to contact its activators and substrates.
Regulation (change) of BRAF
5) Confidence 0.17 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991030 Disease Relevance 0.71 Pain Relevance 0.38
The binding of autoantibodies to BRAF's catalytic domain may result in a change in BRAF conformation and stabilise BRAF in an active conformation allowing the kinase domain to contact its activators and substrates.
Regulation (change) of BRAF
6) Confidence 0.17 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991030 Disease Relevance 0.65 Pain Relevance 0.37
However, the classical gene alterations involved in cell transformation, such as ras, BRAF, Rb, do not appear to be responsible for the onset of pituitary adenomas [3].
Regulation (responsible) of BRAF in pituitary associated with pituitary cancer
7) Confidence 0.13 Published 2006 Journal Cell Div Section Body Doc Link PMC1563461 Disease Relevance 1.21 Pain Relevance 0.08
We have previously demonstrated the utility of our approach by measuring the effect of oncogenic B-Raf depletion in a mouse model of metastatic melanoma.
Regulation (effect) of B-Raf associated with melanoma
8) Confidence 0.10 Published 2007 Journal BMC Biotechnol Section Body Doc Link PMC2174931 Disease Relevance 0.42 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox